We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Cenkos Securities Plc | LSE:CNKS | London | Ordinary Share | GB00B1FLHR07 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 29.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
23/3/2023 09:37 | The chairwoman agrees an all-share merger after a 20% fall in the share price... and after putting out a set of results that is uninspiring to say the least. She must have no confidence in the ability of her CEO; and trying desperately to save her job. Whew. That's a sad end to an old thoroughbred. | needleboy | |
23/3/2023 09:01 | Don't like co-CEO's sets the wrong tone | makinbuks | |
23/3/2023 08:50 | Future powerhouse and sector dominant player. Merger at cyclical lows. When the sector up-cycle eventually begins, this merger should prosper. Patience. | quepassa | |
23/3/2023 08:19 | They will survive as long as they don’t overpay staff. All the small players are struggling so no big players out there offering big bucks. Panmure Gordon might have cash backing but they are very average in their offerings. | chillpill | |
23/3/2023 07:59 | Survival throw of the dice. | grahamg8 | |
23/3/2023 07:44 | Makes u wonder what state the others are in ..... imo dire ! | amaretto1 | |
23/3/2023 07:39 | There is a certain amount of irony here dating back 15 years. I think it makes sense as long as ego’s can prevail. Many of their competitors are likely to fail. Broking firms should not be listed imo. Hindsight is easy but I would argue both should have build wealth/ fund management businesses to protect against market volatility. | chillpill | |
23/3/2023 07:23 | Nil premium merger Insider shareholders seem supportive Disappointing for CNKS. Share swap at very low share price levels All the rhetoric is around management preservation and co CEOs. No financial synergies disclosed. Tells you everything Current trading must be dire. FinnCap will be grateful for the CNKS cash balance | albert zog | |
23/3/2023 07:22 | It looks like we'll also get 3.5p in dividends before the merger is effective. It looks a reasonable enough deal to me. | arthur_lame_stocks | |
23/3/2023 07:07 | So 50:50 maybe why the share price fell so far , no actual bid / money to be made | fenners66 | |
22/3/2023 22:25 | I wonder how much of the combined group CNKS shareholders will get? | arthur_lame_stocks | |
22/3/2023 21:06 | https://news.sky.com | kevph | |
22/3/2023 21:02 | https://twitter.com/ | kevph | |
22/3/2023 16:01 | Loss of mandate... OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease, diabetes and skincare, announces that the Company gave three months' notice to its joint broker Cenkos Securities plc on 28 December 2022. As of 28 March 2023, that notice will be served and Cenkos will cease to be the Company's joint broker. Peterhouse Capital will remain as the Company's sole broker. | speedsgh | |
13/3/2023 23:49 | Picked up more today. Future depends on deals they can do. Instantly turn into receivables. May 2023 bring good bigger deals.Bring back Durkin as Chairman???DYOR | martomarto | |
13/3/2023 13:53 | Seems the market can ignore it.... | fenners66 | |
13/3/2023 11:52 | The HSBC purchase of SVB UK is potentially very positive for the UK tech sector where Cenkos has great traction. Amidst a plethora of highly supportive announcements from various regulatory authorities, the statement from HSBC itself is very interesting:- hXXps://www.hsbc.com One cannot ignore the clear emphasis, support and national importance which has been pronounced from all corners of the UK government for the sector. ALL IMO. DYOR. QP | quepassa | |
10/3/2023 20:28 | Deserve all they get for acting as a Defence Counsel, err sorry NOMAD, assisting the shysters, err sorry, the appalling management at Mercantile and Ports (MPL) over the last 13 years. | mount teide | |
10/3/2023 18:43 | An argument for the stock has been it is underpinned by cash. No explanation must be of concern. | stevenlondon3 | |
10/3/2023 11:38 | Does anyone know why the a large outflow (c. £17m) in payables and what these represent? | velocytongo | |
10/3/2023 10:34 | More like "Racing to the Bottom" | fenners66 | |
10/3/2023 07:48 | Not looking good - Next domino to fall??????????? Highlights 31-Dec-22 31-Dec-21 change Revenue £20.3m £37.2m - 46% Underlying profit (1) (2) £0.2m £4.4m - 95% (Loss) / profit before tax £(2.7)m £4.0m - 168% (Loss) / profit after tax £(2.2)m £3.4m - 165% Cash £14.2m £33.5m - £19.2m Net assets £21.8m £27.0m - £5.2m Basic earnings per share (4.9)p 7.1p Full year dividend per share paid and proposed (3) 1.5p 4.25p (1) Underlying profit is profit before the impact of the day 1 value of options and warrants received in the period and the associated fair value gains and losses on the options and warrants held, restructuring costs and costs associated with incentive plans. (2) The comparative figures have been restated to reflect the current definition of underlying profit. In the current period, in addition to adjusting for restructuring costs and costs associated with incentive plans, this is disclosed before the impact of the day one value of options and warrants received in the period and the associated fair value gains and losses on the options and warrants held. The Directors believe this provides a clearer view of the operational performance of the business in the period as their lifespan may overlap several periods before crystallisation. (3) Includes a proposed final dividend of 0.5p (2021: 3.0p) Outlook: The tough conditions of 2022 have eased slightly in the early part of 2023 but capital markets remain subdued relative to 2021. Despite this, we believe that our ongoing emphasis on working closely with clients and maintaining a proactive dialogue with investors will continue to generate opportunities and attract new clients. Our business model enables us to generate cash at an operational level and profits even in difficult market conditions and our perseverance means we are well placed as markets begin to recover. We believe our gains in market share, selective hiring of quality individuals and teams, a growing client base and a disciplined approach to costs, put us on the front foot to deliver success for our clients, colleagues and shareholders alike. | pugugly | |
07/3/2023 13:28 | Possible involvement of Cenkos in this AUD2.55m placing for Artemis Resources Ltd (AIM:ARV). No confirmation of Cenkos' involvement in the rns but they are listed as the only broker in the footer. | speedsgh | |
17/2/2023 07:49 | Re Creo Medical fundraising. Placing/subscription was oversubscribed and increased to £28.5m. | speedsgh | |
16/2/2023 07:27 | Proposed Placing and Subscription to raise a minimum of £25.0 million for Creo Medical Group plc. Cenkos and Numis are acting as joint bookrunners and joint brokers in relation to the Fundraising. | tanneg |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions